Rebecca Smith-Bindman

Aug 28, 2023 | jamanetwork.com | Sanket S Dhruva |Rebecca Smith-Bindman |Rita F. Redberg

The Need for Randomized Clinical Trials Demonstrating Reduction in All-Cause Mortality With Blood Tests for Cancer Screening In recent years, blood tests that look for circulating tumor DNA and biomarkers (termed liquid biopsies) have been developed. As Carr and Welch describe in this issue of JAMA Internal Medicine,1 these tests are being explored for diagnosis of suspected cancer, cancer surveillance after treatment, response to therapy, and chemotherapeutic selection.